Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

Can you think of a good reason to withhold the dosing information from the clinical registry?
There might be one but I don't know what it could be.

The final B-ABSSSI trial listing provided a detailed description of the dosing regimen used in that trial:
"Eligible subjects will be randomized to one of 4 treatment groups in a 1:1:1:1 ratio. Subjects randomized to brilacidin will receive either a single intravenous infusion (0.6 mg/kg or 0.8 mg/kg) followed by six days of once daily placebo, or a three day regimen (0.6 mg/kg on Day 1 followed by 0.3 mg/kg on Days 2 and 3) followed by 4 days of once daily placebo. Subjects randomized to daptomycin will receive 7 days of treatment."